Barclays
KLDO

Barclays’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Barclays’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,146
Closed -$5K – 5513
2022
Q1 		$5K Sell
3,146
-20,367
-87% -$36.3K ﹤0.01% 4710
2021
Q4 		$56K Buy
23,513
+15,593
+197% +$63.5K ﹤0.01% 3829
2021
Q3 		$43K Buy
7,920
+4,122
+109% +$25.6K ﹤0.01% 4144
2021
Q2 		$28K Sell
3,798
-7,799
-67% -$55.3K ﹤0.01% 4398
2021
Q1 		$93K Buy
11,597
+7,708
+198% +$84K ﹤0.01% 4034
2020
Q4 		$35K Sell
3,889
-1,413
-27% -$11.6K ﹤0.01% 4551
2020
Q3 		$59K Sell
5,302
-520
-9% -$3.6K ﹤0.01% 4517
2020
Q2 		$43K Buy
5,822
+2,047
+54% +$13.7K ﹤0.01% 4997
2020
Q1 		$23K Sell
3,775
-7,588
-67% -$49.5K ﹤0.01% 5605
2019
Q4 		$57K Buy
11,363
+8,876
+357% +$56.4K ﹤0.01% 5707
2019
Q3 		$19K Sell
2,487
-765
-24% -$6.64K ﹤0.01% 6231
2019
Q2 		$38K Sell
3,252
-595
-15% -$8.66K ﹤0.01% 6216
2019
Q1 		$56K Buy
+3,847
New +$52.9K ﹤0.01% 5794

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Barclays's KLDO Position: Q2 2022 in Review

Barclays sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 3,146 shares — an estimated $5K sold.

Barclays first reported a position in KLDO in Q1 2019 and held it in 13 quarters. The position peaked at $93K in Q1 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • Barclays reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 3,146 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $5K.
  • Barclays first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
  • Barclays's Kaleido Biosciences, Inc. Common Stock position peaked at $93K in Q1 2021.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.